Treatment option for erectile dysfunction

Journal of Internal Medicine of India

Volumn 4, Issue 4, 2001, Pages 198-209

  Raina, R ^a   Khattri, S ^a   Thukral, M ^a   Lakin, M M ^a   Agarwal, A ^a   Zippe, C D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOMORPHINE; MINIDOXIL; NITROUS OXIDE; POTASSIUM CHANNEL AFFECTING AGENT; PROSTAGLANDIN E1; SILDENAFIL; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; NAUSEA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035710062     PISSN: 09721096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Impotence
2. Minimally invasive therapy for erectile dysfunction: Intracavernosal, oral, transdermal/transglandular and intraurethral approaches
3. Physiology of penile erection
4. Nitic oxide as a mediator of the corpus cavernosum in response to non cholenergic non adrenergic neurotransmission
5. Potassium channel openers for relaxation of isolated erectile tissue from rabbit
6. Modulation of vasoactive intestinal peptide (VIP) mediated relaxation by nitric oxide and prostenoids in the rabbit corpous cavernosum
7. VIP and other bioactive substance involved in penile erection
8. Charecterization of contracting and relaxing agents in human and rabbit corpus cavernosum
9. Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence
10. Vacuum constriction devices for erectile dysfunction: A long-term, prospective study of patients with mild, moderate, and severe dysfunction
11. Long term results with vacuum constriction device
12. Twelve-month comparison of two treatments for erectile dysfunction: Self-injection versus external vacuum devices
13. Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction
14. External vacuum devices: A clinical comparison with pharmacologic erections
15. Use of vacuum tumescence device for impotence secondary to venous leakage
16. Patient acceptance of and satisfaction with an external negative pressure device for impotence
17. Does early treatment of erectile dysfunction after nerve sparing radical prostatectomy lead to better long term return of natural function?
18. Successful non-invasive management of erectile impotence in diabetic men
19. Minidoxil and capsacin: An association of transcutaneous active drugs for erection facilitation
20. Topical glycerylternitate causes penile arterial diltation in impotent man
21. Nitroglycerine ointment in the treatment of impotence
22. Minidoxil versus nitroglycerine: Prospective double blind control trial in transcutaneous erection facilitation for organic impotence
23. Topical prostaglandin El SEPA gel for treatment of erctile dysfunction
24. Treatment of men with erectile dysfunction with transurethral alprostadil
25. Safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy
26. Transurethral alprostadil with MUSE versus intracavernous alprostadil: A comparative study in 103 patients with erectile dysfunction
27. Pilot experiments on the action of drugs injected into the human corpus cavemosum penis
28. Prostaglandin E-1 in the treatment of erectile dysfunction
29. The role of prostaglandins in the etiology and treatment of erectile dysfunction
30. A pilot study for the role of intracavemosal injection of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction
31. Prostaglandin E1 injection therapy for post-prostatectomy impotence: An outcome analysis
32. Complications of intracavernosal therapy for impotence
33. The causes of patient dropout from penile self-injection therapy for impotence
34. Intracavernosal therapy for erectile failure-impact of treatment and reasons for dropout and dissatisfaction
35. Management of erectile dysfunction following radical prostatectomy
36. PGE1 suppresses the induction of collagen synthesis by transforming growth factor beta 1 in human corpus cavernosum smooth muscle
37. Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical prostatectomy
38. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial
39. For the Sildenafil Study Group: Oral sildenafil in the treatment of erectile dysfunction
40. Three year update of sildenafil citrate (Viagra) efficacy and safety
41. Nitric oxide as a mediator of the corpus cavernosum in response to non-cholinergic non-adrenergic neurotransmission
42. Sildenafil: A novel inhibitor of phoshodiesterase type 5 in human corpus cavernosum smooth muscle cells
43. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isoenzymes
44. Role of Viagra after radical prostatectomy
45. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra)
46. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy
47. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
48. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction
49. Sildenafil taken at bedtime significantly increases nocturnal erectile activity: Results of a prospective Rigiscan study
50. Nocturnal penile tumescence activity in 81 patients presenting with erectile dysfunction after nerve sparing radical prostatectomy
51. Predictive value of nocturnal penile tumescence (NPT) on long term return of erectile function in men with erectile dysfunction (ED) after nerve sparing radical prostatectomy (NSRRP)
52. Sildenafil citrate (Viagra) after radical retropubic prostatectomy: Pro.